We are live on ! Find out more
NVS icon

Novartis

1,172 hedge funds and large institutions have $24.4B invested in Novartis in 2019 Q4 according to their latest regulatory filings, with 156 funds opening new positions, 412 increasing their positions, 387 reducing their positions, and 55 closing their positions.

New
Increased
Maintained
Reduced
Closed

184% more first-time investments, than exits

New positions opened: 156 | Existing positions closed: 55

64% more funds holding in top 10

Funds holding in top 10: 1423 (+9)

55% more call options, than puts

Call options by funds: $200M | Put options by funds: $129M

15% more capital invested

Capital invested by funds: $21.2B → $24.4B (+$3.18B)

8% more funds holding

Funds holding: 1,0901,172 (+82)

6% more repeat investments, than reductions

Existing positions increased: 412 | Existing positions reduced: 387

0.54% more ownership

Funds ownership: 9.57%10.11% (+0.54%)

Holders
1,172
Holders Change
+82
Holders Change %
+7.52%
% of All Funds
23.09%
Holding in Top 10
23
Holding in Top 10 Change
+9
Holding in Top 10 Change %
+64.29%
% of All Funds
0.45%
New
156
Increased
412
Reduced
387
Closed
55
Calls
$200M
Puts
$129M
Net Calls
+$71M
Net Calls Change
+$62.6M
Name Holding Trade Value Shares
Change
Change in
Stake
WIC
151
Wilkins Investment Counsel
Massachusetts
$11.6M +$47.1K +525 +0.4%
MIM
152
Martin Investment Management
Florida
$11.6M +$226K +2,521 +2%
TBA
153
Tower Bridge Advisors
Pennsylvania
$11.4M +$632K +7,048 +6%
Jones Financial Companies
154
Jones Financial Companies
Missouri
$11.4M +$71.7K +799 +0.7%
AAM
155
Advisors Asset Management
Colorado
$11.2M +$690K +7,695 +7%
GHA
156
GW Henssler & Associates
Georgia
$11.2M +$636K +7,090 +6%
RCYC
157
Richard C. Young & Co
Rhode Island
$10.6M +$216K +2,411 +2%
TCOV
158
Trust Company of Vermont
Vermont
$10.3M -$94.2K -1,050 -1%
TG
159
TCW Group
California
$10.3M +$326K +3,631 +3%
AAIM
160
American Assets Investment Management
California
$10.3M
CSIC
161
Clifford Swan Investment Counsel
California
$10.2M -$694K -7,739 -7%
FT
162
Fiduciary Trust
Massachusetts
$10.1M -$286K -3,185 -3%
AIA
163
Avalon Investment & Advisory
Texas
$10.1M +$765K +8,530 +9%
VanEck Associates
164
VanEck Associates
New York
$10.1M +$2.25M +25,077 +31%
BC
165
Brinker Capital
Pennsylvania
$9.75M +$606K +6,758 +7%
DP
166
DDD Partners
Washington
$9.63M -$170K -1,895 -2%
GT
167
Glenmede Trust
Pennsylvania
$9.57M -$54.5K -607 -0.6%
RG
168
Rathbones Group
United Kingdom
$9.47M +$102K +1,142 +1%
ECG
169
Edge Capital Group
Georgia
$9.46M -$1.3M -14,539 -13%
CGH
170
Crossmark Global Holdings
Texas
$9.4M +$2.08M +23,182 +30%
MJP
171
Michael J. Puzo
$9.39M -$69.1K -770 -0.8%
CT
172
Cambridge Trust
Massachusetts
$9.38M +$163K +1,816 +2%
GF
173
Gabelli Funds
New York
$9.37M -$89.7K -1,000 -1%
Ensign Peak Advisors
174
Ensign Peak Advisors
Utah
$9.13M +$8.65M +96,448 New
Northwestern Mutual Wealth Management
175
Northwestern Mutual Wealth Management
Wisconsin
$9.01M +$652K +7,265 +8%

NVS Hedge Fund Activity: Q4 2019 in Review

1,172 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q4 2019, worth a combined $24.4B — up 15% from $21.2B a quarter earlier.

Buyers outnumbered sellers: 156 funds opened new NVS positions and 55 closed out — a net gain of 101 holders — while 412 added to existing stakes and 387 trimmed.

The largest buyer was Loomis, Sayles & Company, adding an estimated $284M. The largest seller was Dodge & Cox, cutting an estimated $140M.

  • 1,172 institutional investors held Novartis (NVS) as of Q4 2019, up from 1,090 in Q3 2019.
  • Funds reported $24.4B of Novartis stock for Q4 2019, up 15% quarter-over-quarter.
  • 156 funds opened new Novartis positions in Q4 2019 and 55 closed out, a net change of +101 holders.
  • The largest Novartis buyer in Q4 2019 was Loomis, Sayles & Company, an estimated $284M added.
  • The largest Novartis seller in Q4 2019 was Dodge & Cox, an estimated $140M sold.

Based on aggregated 13F filings for Q4 2019.